Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy

Cellular Signalling

Volumn 28, Issue 9, 2016, Pages 1412-1421

  Grzmil, Michal ^a,b   Seebacher, Jan ^a   Hess, Daniel ^a   Behe, Martin ^b   Schibli, Roger ^b,c   Moncayo, Gerald ^a   Frank, Stephan ^d   Hemmings, Brian A ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

eIF4E; eIF4G; Glioma; MNK; MTC; Temozolomide

Indexed keywords

CERCOSPORAMIDE; CGP 57380; GASTRIN DERIVATIVE; INITIATION FACTOR 4E; LUTETIUM 177; MAP KINASE INTERACTING KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RADIOISOTOPE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; DACARBAZINE; GASTRIN; INITIATION FACTOR 4G; LUTETIUM; LUTETIUM-177; MKNK1 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PURINE DERIVATIVE; SIGNAL PEPTIDE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; GLIOBLASTOMA CELL LINE; GLIOMA CELL; HUMAN; HUMAN CELL; ISOTOPE LABELING; MEDULLARY THYROID CARCINOMA CELL; MUTATIONAL ANALYSIS; PHOSPHOPROTEOMICS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; DRUG EFFECTS; GLIOMA; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; EUKARYOTIC INITIATION FACTOR-4E; EUKARYOTIC INITIATION FACTOR-4G; GASTRINS; GLIOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUTETIUM; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; PURINES; RADIOISOTOPES; SIGNAL TRANSDUCTION;

EID: 84976420292     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2016.06.005     Document Type: Article

References (43)

1. [1] Dolecek, T.A., Propp, J.M., Stroup, N.E., Kruchko, C., CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncology 14:Suppl. 5 (2012), v1–49.
2. [2] Bower, M., Newlands, E.S., Bleehen, N.M., Brada, M., Begent, R.J., Calvert, H., Colquhoun, I., Lewis, P., Brampton, M.H., Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol. 40 (1997), 484–488.
3. [3] Osoba, D., Brada, M., Yung, W.K., Prados, M., Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. 18 (2000), 1481–1491.
4. [4] Gerson, S.L., Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 20 (2002), 2388–2399.
5. [5] Hegi, M.E., Liu, L., Herman, J.G., Stupp, R., Wick, W., Weller, M., Mehta, M.P., Gilbert, M.R., Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26 (2008), 4189–4199.
6. [6] Dorsam, R.T., Gutkind, J.S., G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7 (2007), 79–94.
7. [7] Behr, T.M., Behe, M.P., Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin. Nucl. Med. 32 (2002), 97–109.
8. [8] Begg, A.C., Stewart, F.A., Vens, C., Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 11 (2011), 239–253.
9. [9] Grzmil, M., Hemmings, B.A., Translation regulation as a therapeutic target in cancer. Cancer Res. 72 (2012), 3891–3900.
10. [10] Lu, X., de la Pena, L., Barker, C., Camphausen, K., Tofilon, P.J., Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes. Cancer Res. 66 (2006), 1052–1061.
11. [11] Sonenberg, N., Hinnebusch, A.G., Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136 (2009), 731–745.
12. [12] Larsson, O., Li, S., Issaenko, O.A., Avdulov, S., Peterson, M., Smith, K., Bitterman, P.B., Polunovsky, V.A., Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 67 (2007), 6814–6824.
13. [13] Mamane, Y., Petroulakis, E., Martineau, Y., Sato, T.A., Larsson, O., Rajasekhar, V.K., Sonenberg, N., Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One, 2, 2007, e242.
14. [14] Hayman, T.J., Williams, E.S., Jamal, M., Shankavaram, U.T., Camphausen, K., Tofilon, P.J., Translation initiation factor eIF4E is a target for tumor cell radiosensitization. Cancer Res. 72 (2012), 2362–2372.
15. [15] Buxade, M., Parra-Palau, J.L., Proud, C.G., The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front. Biosci. 13 (2008), 5359–5373.
16. [16] Wendel, H.G., Silva, R.L., Malina, A., Mills, J.R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., Lowe, S.W., Dissecting eIF4E action in tumorigenesis. Genes Dev. 21 (2007), 3232–3237.
17. [17] Korur, S., Huber, R.M., Sivasankaran, B., Petrich, M., Morin, P. Jr., Hemmings, B.A., Merlo, A., Lino, M.M., GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One, 4, 2009, e7443.
18. [18] Knauf, U., Tschopp, C., Gram, H., Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol. Cell. Biol. 21 (2001), 5500–5511.
19. [19] Yanagiya, A., Svitkin, Y.V., Shibata, S., Mikami, S., Imataka, H., Sonenberg, N., Requirement of RNA binding of mammalian eukaryotic translation initiation factor 4GI (eIF4GI) for efficient interaction of eIF4E with the mRNA cap. Mol. Cell. Biol. 29 (2009), 1661–1669.
20. [20] McAlister, G.C., Nusinow, D.P., Jedrychowski, M.P., Wuhr, M., Huttlin, E.L., Erickson, B.K., Rad, R., Haas, W., Gygi, S.P., MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. Anal. Chem. 86 (2014), 7150–7158.
21. [21] Cox, J., Mann, M., MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26 (2008), 1367–1372.
22. [22] Cox, J., Neuhauser, N., Michalski, A., Scheltema, R.A., Olsen, J.V., Mann, M., Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10 (2011), 1794–1805.
23. [23] Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C.J., McLauchlan, H., Klevernic, I., Arthur, J.S., Alessi, D.R., Cohen, P., The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408 (2007), 297–315.
24. [24] Hou, J., Lam, F., Proud, C., Wang, S., Targeting Mnks for cancer therapy. Oncotarget 3 (2012), 118–131.
25. [25] Dennis, G. Jr., Sherman, B.T., Hosack, D.A., Yang, J., Gao, W., Lane, H.C., Lempicki, R.A., DAVID: database for annotation, visualization, and integrated discovery. Genome Biol., 4, 2003, P3.
26. [26] Huang da, W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4 (2009), 44–57.
27. [27] Zhang, Y., Li, Y., Yang, D.Q., Phosphorylation of eIF-4E positively regulates formation of the eIF-4F translation initiation complex following DNA damage. Biochem. Biophys. Res. Commun. 367 (2008), 54–59.
28. [28] Waskiewicz, A.J., Flynn, A., Proud, C.G., Cooper, J.A., Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 16 (1997), 1909–1920.
29. [29] Fukunaga, R., Hunter, T., MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 16 (1997), 1921–1933.
30. [30] Braunstein, S., Badura, M.L., Xi, Q., Formenti, S.C., Schneider, R.J., Regulation of protein synthesis by ionizing radiation. Mol. Cell. Biol. 29 (2009), 5645–5656.
31. [31] Holt, S.V., Logie, A., Odedra, R., Heier, A., Heaton, S.P., Alferez, D., Davies, B.R., Wilkinson, R.W., Smith, P.D., The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br. J. Cancer 106 (2012), 858–866.
32. [32] Sheth, K., Friel, J., Nolan, B., Bankey, P., Inhibition of p38 mitogen activated protein kinase increases lipopolysaccharide induced inhibition of apoptosis in neutrophils by activating extracellular signal-regulated kinase. Surgery 130 (2001), 242–248.
33. [33] Croons, V., Martinet, W., Herman, A.G., Timmermans, J.P., De Meyer, G.R., The protein synthesis inhibitor anisomycin induces macrophage apoptosis in rabbit atherosclerotic plaques through p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther. 329 (2009), 856–864.
34. [34] Ueda, T., Watanabe-Fukunaga, R., Fukuyama, H., Nagata, S., Fukunaga, R., Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol. Cell. Biol. 24 (2004), 6539–6549.
35. [35] Grzmil, M., Huber, R.M., Hess, D., Frank, S., Hynx, D., Moncayo, G., Klein, D., Merlo, A., Hemmings, B.A., MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas. J. Clin. Invest. 124 (2014), 742–754.
36. [36] Furic, L., Rong, L., Larsson, O., Koumakpayi, I.H., Yoshida, K., Brueschke, A., Petroulakis, E., Robichaud, N., Pollak, M., Gaboury, L.A., Pandolfi, P.P., Saad, F., Sonenberg, N., eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 14134–14139.
37. [37] Grzmil, M., Morin, P. Jr., Lino, M.M., Merlo, A., Frank, S., Wang, Y., Moncayo, G., Hemmings, B.A., MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma. Cancer Res. 71 (2011), 2392–2402.
38. [38] Shi, Y., Frost, P., Hoang, B., Yang, Y., Fukunaga, R., Gera, J., Lichtenstein, A., MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells. Oncogene 32 (2013), 190–197.
39. [39] Robichaud, N., del Rincon, S.V., Huor, B., Alain, T., Petruccelli, L.A., Hearnden, J., Goncalves, C., Grotegut, S., Spruck, C.H., Furic, L., Larsson, O., Muller, W.J., Miller, W.H., Sonenberg, N., Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene 34 (2015), 2032–2042.
40. [40] Badura, M., Braunstein, S., Zavadil, J., Schneider, R.J., DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 18767–18772.
41. [41] Dobrikov, M., Dobrikova, E., Shveygert, M., Gromeier, M., Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) by protein kinase C{alpha} regulates eIF4G1 binding to Mnk1. Mol. Cell. Biol. 31 (2011), 2947–2959.
42. [42] Dobrikov, M.I., Dobrikova, E.Y., Gromeier, M., Dynamic regulation of the translation initiation helicase complex by mitogenic signal transduction to eukaryotic translation initiation factor 4G. Mol. Cell. Biol. 33 (2013), 937–946.
43. [43] Diab, S., Kumarasiri, M., Yu, M., Teo, T., Proud, C., Milne, R., Wang, S., MAP kinase-interacting kinases–emerging targets against cancer. Chem. Biol. 21 (2014), 441–452.